RA Capital Discloses 14.3% Stake in Freenome Post-Merger, Including $52.6M PIPE Investment
Summary
RA Capital Management reports a 14.3% stake in Freenome after the SPAC merger closed, including a $52.6 million PIPE investment at $10 per share. The position is locked up for six months but carries registration rights.
Key Events · Ownership and Investor Activity · PCSC
-
14.3% Stake Established
RA Capital and affiliates beneficially own 15,367,270 shares (14.3% of 107.4M outstanding), making them one of the largest shareholders post-merger.
-
$52.6M PIPE Investment
The fund and Nexus Fund III purchased 5,255,376 shares at $10.00 per share in the PIPE financing, providing fresh capital to Freenome.
-
Legacy Equity Conversion
9,361,894 shares were received in exchange for existing Freenome equity interests, representing a $219M aggregate investment prior to the merger.
-
Six-Month Lock-Up
All shares are subject to a lock-up agreement restricting transfers until January 20, 2027, preventing immediate selling pressure.
Analysis · PCSC · Industrial Applications And Services
RA Capital Management, a major healthcare investor, now holds 15.4 million shares of Freenome (14.3% of outstanding) following the SPAC merger close. The filing details $52.6 million in fresh capital deployed at $10 per share in the PIPE, alongside the conversion of $219 million in prior Freenome equity. The stake is locked up for six months, but registration rights could create overhang once effective. This is a strong institutional endorsement of the newly public cancer screening company, but the large position also means any future sales could pressure the stock.
At the time of this filing, PCSC was trading at $12.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $123.2M. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.